Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.2915
Abstract: Importance Rechallenge therapy with anti-epidermal growth factor receptor (EGFR) drugs has been suggested in patients with chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC) after initial response to anti-EGFR-based first-line treatment. The association of treatment… read more here.
Keywords: trial; cetuximab; months months; rechallenge ... See more keywords
Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-4222-x
Abstract: BackgroundData are sparse regarding the feasibility of radioligand therapy (RLT) with [177Lu]Lu-PSMA-617 as a retreatment. We aimed to assess the outcome and safety of rechallenge PSMA-RLT in patients with progressive prostatic cancer who previously benefited… read more here.
Keywords: psma rlt; baseline psma; rechallenge; adverse events ... See more keywords
Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03913-3
Abstract: The aim of this multicenter study was to evaluate the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib retreatment. Clinical data from patients treated with sunitinib rechallenge in nine Spanish… read more here.
Keywords: renal cell; cell carcinoma; sunitinib rechallenge; study ... See more keywords
Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology Reports"
DOI: 10.1007/s11912-022-01241-z
Abstract: The reintroduction of immune checkpoint inhibitors (ICIs) after disease progression (rechallenge) or immune-related adverse events (irAEs) recovering (resumption) raises questions in terms of efficacy and safety. Here, we reviewed literature data about ICIs rechallenge/resumption in… read more here.
Keywords: rechallenge resumption; checkpoint inhibitor; resumption; immune checkpoint ... See more keywords
Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer
Sign Up to like & getrecommendations! Published in 2018 at "Medical Oncology"
DOI: 10.1007/s12032-018-1123-6
Abstract: Among patients with relapsed small-cell lung cancer (SCLC), those who relapse > 90 days after first-line chemotherapy are classified sensitive relapse. Rechallenge with a first-line platinum-based regimen has been used in sensitive relapsed SCLC patients, but its importance… read more here.
Keywords: chemotherapy; platinum based; line; rechallenge ... See more keywords
Is chemotherapy rechallenge feasible in advanced-stage non-small-cell lung cancer?
Sign Up to like & getrecommendations! Published in 2019 at "Bulletin du cancer"
DOI: 10.1016/j.bulcan.2019.04.010
Abstract: BACKGROUND Despite recent progress, non-small cell lung cancer (NSCLC) first-line treatment remains a platinum-based doublet in most cases. No guidelines exist beyond third line. Chemotherapy rechallenge is an option, but little data is available in… read more here.
Keywords: line; treatment; chemotherapy rechallenge; rechallenge ... See more keywords
Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
Sign Up to like & getrecommendations! Published in 2020 at "Current problems in cancer"
DOI: 10.1016/j.currproblcancer.2020.100668
Abstract: INTRODUCTION Anaplastic thyroid carcinoma (ATC) is a highly aggressive, undifferentiated rare tumor. Median overall survival is usually between 8 and10 months, with a 1-year survival rate of 20%. Conventional anthracycline based chemotherapy regimens demonstrate low… read more here.
Keywords: anaplastic thyroid; dabrafenib; case; rechallenge ... See more keywords
Rechallenge clozapine after agranulocytosis in refractory schizophrenia. A case report
Sign Up to like & getrecommendations! Published in 2017 at "European Psychiatry"
DOI: 10.1016/j.eurpsy.2017.01.1411
Abstract: Introduction Clozapine, is widely prescribed for treatment of refractory schizophrenia, but its use may be limited by potentially serious adverse effects. The most feared complication remains agranulocytosis [absolute neutrophil count (ANC) Objectives To know procedures… read more here.
Keywords: schizophrenia; rechallenge; refractory schizophrenia; agranulocytosis refractory ... See more keywords
Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz255.039
Abstract: Abstract Background Combination IPI+PD1 immunotherapy has a high initial response rate, but patients can subsequently progress. The best management of this acquired resistance is unknown. We sought to explore the efficacy and safety of rechallenge… read more here.
Keywords: ipi pd1; rechallenge; consultancy; advisory consultancy ... See more keywords
The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyz066
Abstract: INTRODUCTION Immune checkpoint inhibitors (ICIs) have demonstrated long survival for the treatment of advanced non-small cell lung cancer (NSCLC). However, the effect and safety of ICI rechallenge have not been fully evaluated. The aim of… read more here.
Keywords: immune checkpoint; safety; effect; ici rechallenge ... See more keywords
1787. The Safety and Efficacy of an Oral Penicillin Rechallenge Program in Cancer Patients: A Pilot Multicenter Study
Sign Up to like & getrecommendations! Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy210.1443
Abstract: Abstract Background Patient-reported antibiotic allergies (so-called antibiotic allergy labels [AALs]) are found in one in four cancer patients and significantly impact patient outcomes. Whilst 85% of AALs can be removed by skin testing, the role… read more here.
Keywords: oral penicillin; program; penicillin rechallenge; rechallenge ... See more keywords